Posted: January 20, 2022 at 2:09 am
Accomplished academic and industry veteran with a successful record developing treatments for B cell lymphoma Accomplished academic and industry veteran with a successful record developing treatments for B cell lymphoma
Read the original post:
Foresight Diagnostics Establishes Scientific Advisory Board with Appointment of Sandra Horning, M.D.
Posted: January 20, 2022 at 2:09 am
AGOURA HILLS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a leading developer of TGF-? therapeutics for oncology and virology, today announced that Dr. Vuong Trieu, Oncotelic Chairman and CEO, will be presenting the Company immunotherapy pipeline at BiotechGate Digital Partnering Feb 7 - 11, 2022.
View original post here:
Oncotelic Presenting at BiotechGate Digital Partnering
Posted: January 20, 2022 at 2:09 am
SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the US Phase 2 study (www.ClinicalTrials.gov NCT04906694) with intranasal COVI-DROPS treatment in COVID-19 outpatients has completed enrollment. This preliminary efficacy study enrolled 72 adult outpatients who received a single administration of 10 mg, 20 mg or 40 mg COVI-DROPS or placebo, randomized 1:1:1:1. The primary endpoint was viral load reduction from baseline. Key secondary endpoints included the proportion of subjects with medically-attended visits or hospitalizations and the change from baseline in the WHO Clinical Progression Scale score. There were no significant safety events reported during this study.
Posted: January 20, 2022 at 2:09 am
Company announcement – No. 2 / 2021
Read more here:
Zealand Pharma major shareholder announcement: The Capital Group Companies, January 2022
Posted: January 20, 2022 at 2:09 am
-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 ---- Fourth Quarter 2022 net sales for UPNEEQ targeted to range from $20-$25 million --
See the original post:
UPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch...
Posted: January 20, 2022 at 2:09 am
1 Change at constant exchange rates and scope corresponds to organic growth of sales, excluding exchange rate variations, by calculating the indicator for the financial year in question and the indicator for the previous financial year on the basis of identical exchange rates (the exchange rate used is the previous financial year’s), and excluding change in scope, by calculating the indicator for the financial year in question on the basis of the scope of consolidation for the previous financial year, and excluding sales of Sentinel, a product that was sold on July 1, 2020, over the first two half-years in question.
Read this article:
VIRBAC: Exceptional growth in annual revenue of +18.4% at comparable exchange rates and scope (+14.9% at constant rates and real scope), driven by...
Posted: January 20, 2022 at 2:09 am
PRESS RELEASE
Read more from the original source:
AB Science has been granted authorization to initiate Phase II study in patients with severe mast cell activation syndrome by the French Health...
Posted: January 20, 2022 at 2:09 am
Saint Herblain (France), January 19, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced results from an initial laboratory study demonstrating that serum antibodies induced by three doses of Valneva’s inactivated COVID-19 vaccine candidate, VLA2001, neutralize the Omicron variant.
Read more:
Valneva’s Inactivated COVID-19 Vaccine Candidate Shown to Neutralize Omicron Variant
Posted: January 20, 2022 at 2:09 am
SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") and Sorrento Mexico today announced that approximately 1,000,000 COVISTIX tests were distributed last week in Mexico. Orders are increasing daily as pent-up demand is high for a sensitive and convenient test that is capable of accurately detecting all of the current variants of the SARS-CoV-2 virus, including the dominant Omicron variant. Millions of additional COVISTIX tests are scheduled to be delivered to Mexico, with tens of millions more being manufactured to support the increasing demand for COVISTIX worldwide. “We believe there is a significant unmet need for a sensitive and rapid antigen test which detects Omicron with high sensitivity even for asymptomatic patients,” stated Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics.
Read this article:
Sorrento Announces That Sorrento Mexico Has Sold Out of One Million COVISTIX Tests Last Week in Mexico
Posted: January 20, 2022 at 2:09 am
Presentation to highlight data from preclinical studies of the company’s next-generation pan-FGFR inhibitor, KIN-3248, and its activity against acquired FGFR gatekeeper and molecular brake drug-resistance mutations Presentation to highlight data from preclinical studies of the company’s next-generation pan-FGFR inhibitor, KIN-3248, and its activity against acquired FGFR gatekeeper and molecular brake drug-resistance mutations
Originally posted here:
Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium
